SM: multivariate analyses of prognostic factors for PFS and OS for the entire patient series (n = 34)
| Disease features . | n . | PFS . | OS . | ||
|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | ||
| Clinical and laboratory features | |||||
| Hemoglobin, g/L | |||||
| <100 | 5 | NT | NS | ||
| ≥100 | 29 | ||||
| Skin lesions | |||||
| No | 10 | NT | NS | ||
| Yes | 24 | ||||
| Platelets, ×109/L | |||||
| <100 | 11 | NS | NS | ||
| ≥100 | 23 | ||||
| β2-microglobulin, µg/mL | |||||
| <2.5 | 7 | NT | NS | ||
| ≥2.5 | 20 | ||||
| SAP, U/L | |||||
| <150 | 16 | NS | NS | ||
| ≥150 | 14 | ||||
| Splenomegaly | |||||
| No | 11 | NS | NS | ||
| Yes | 23 | ||||
| Gene panel mutational status | |||||
| S/A/R | |||||
| WT | 23 | NS | NS | ||
| Mutated | 11 | ||||
| S/A/R/E | |||||
| WT | 19 | 7.6 (2.2-2.6) | .001 | 13.1 (2.7-64) | .001 |
| Mutated | 15 | ||||
| Disease features . | n . | PFS . | OS . | ||
|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | ||
| Clinical and laboratory features | |||||
| Hemoglobin, g/L | |||||
| <100 | 5 | NT | NS | ||
| ≥100 | 29 | ||||
| Skin lesions | |||||
| No | 10 | NT | NS | ||
| Yes | 24 | ||||
| Platelets, ×109/L | |||||
| <100 | 11 | NS | NS | ||
| ≥100 | 23 | ||||
| β2-microglobulin, µg/mL | |||||
| <2.5 | 7 | NT | NS | ||
| ≥2.5 | 20 | ||||
| SAP, U/L | |||||
| <150 | 16 | NS | NS | ||
| ≥150 | 14 | ||||
| Splenomegaly | |||||
| No | 11 | NS | NS | ||
| Yes | 23 | ||||
| Gene panel mutational status | |||||
| S/A/R | |||||
| WT | 23 | NS | NS | ||
| Mutated | 11 | ||||
| S/A/R/E | |||||
| WT | 19 | 7.6 (2.2-2.6) | .001 | 13.1 (2.7-64) | .001 |
| Mutated | 15 | ||||
NS, not statistically significant (P > 0.05); NT, not tested.